For Inflammatory Diseases, Citryll and Lonza Partner to Develop Antibody - Pulmonary Fibrosis News

For Inflammatory Diseases, Citryll and Lonza Partner to Develop Antibody  Pulmonary Fibrosis News

Citryll and Lonza are teaming up to develop the antibody CIT-013 to treat inflammatory diseases, including idiopathic pulmonary fibrosis.